Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cell Source, Inc.CLCS · Entity 9600 | Director | June 30, 2021 | July 07, 2021 |
| TuHURA Biosciences, Inc./NVKTRA · Entity 6601 | Chief Scientific Officer | August 30, 2023 | September 01, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cell Source, Inc.
Report date June 30, 2021 · Filed July 07, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 114,927 |
Reported balance
After 2021-06-30 transaction · row 1
1 source rowRow 1 · 2021-06-30 · Other · Acquired 2,976 · Balance 114,927 F1: Issued as payment-in-kind dividend on Series A Convertible Preferred Stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Issued as payment-in-kind dividend on Series A Convertible Preferred Stock.
TuHURA Biosciences, Inc./NV
Report date August 30, 2023 · Filed September 01, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.66 · Expires 2033-08-30 | Direct | 10,175 |
Reported balance
After 2023-08-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-08-30 · Grant · Acquired 10,175 · Balance 10,175 F1: The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued employment, 25% of the options vest on August 30, 2024, with the remaining shares vesting in 36 equal monthly installments commencing on September 30, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued employment, 25% of the options vest on August 30, 2024, with the remaining shares vesting in 36 equal monthly installments commencing on September 30, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 30, 2023 Filed Sep 1, 2023 22:00 UTC | TuHURA Biosciences, Inc./NV KTRA · Entity 6601 | GrantOptions (Right to Buy) · Derivative | 10,175 | $0.00 Strike: $4.66 | $0.00 |
DisclosureSEC source: 0001493152-23-031534 · ownership.xml · derivative · entry 1 Brown Dennis M · CIK 0001569520 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,175 Underlying: Common Stock · 10,175 shares Expires 2033-08-30 F1 · derivative.exercise_date: The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued employment, 25% of the options vest on August 30, 2024, with the remaining shares vesting in 36 equal monthly installments commencing on September 30, 2024. Read SEC document |
| January 05, 2023 Filed Jan 7, 2023 00:26 UTC | TuHURA Biosciences, Inc./NV KTRA · Entity 6601 | OtherCommon Stock, par value $0.001 per share | 363 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-23-000860 · ownership.xml · nonDerivative · entry 1 Brown Dennis M · CIK 0001569520 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,302 F1 · balance_after: Includes 4,801 restricted stock units that are unvested. Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 20:30 UTC | TuHURA Biosciences, Inc./NV KTRA · Entity 6601 | GrantOption (right to buy) · Derivative | 720,260 | $0.00 Strike: $0.18 | $0.00 |
DisclosureSEC source: 0001493152-22-021171 · ownership.xml · derivative · entry 3 Brown Dennis M · CIK 0001569520 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 720,260 Underlying: Common Stock · 720,260 shares Expires 2022-08-02 F3 · derivative.exercise_date: The option vests as to 25% on August 1, 2023 with the remainder to vest in 36 equal monthly installments thereafter. Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 20:30 UTC | TuHURA Biosciences, Inc./NV KTRA · Entity 6601 | GrantCommon Stock | 240,087 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-021171 · ownership.xml · nonDerivative · entry 1 Brown Dennis M · CIK 0001569520 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,905 F1 · shares: The Reporting Person was granted 240,087 restricted stock units, which will be settled in shares of the Issuer's common stock. The restricted stock units vest in 4 equal annual installments beginning on August 1, 2023. Read SEC document |
| June 30, 2021 Filed Jul 7, 2021 16:53 UTC | Cell Source, Inc. CLCS · Entity 9600 | OtherCommon Stock | 2,976 | $0.75 | $2,232.00 |
DisclosureSEC source: 0001493152-21-016320 · ownership.xml · nonDerivative · entry 1 Brown Dennis M · CIK 0001569520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,927 F1 · kind: Issued as payment-in-kind dividend on Series A Convertible Preferred Stock. Read SEC document |
| April 29, 2021 Filed Apr 29, 2021 20:06 UTC | TuHURA Biosciences, Inc./NV KTRA · Entity 6601 | ConversionSeries B Convertible Preferred Stock · Derivative | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000905718-21-000631 · kintara_fm4apr292021.xml · derivative · entry 4 Brown Dennis M · CIK 0001569520 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of Series B Preferred Stock was convertible into 0.25 shares of common stock equating to a conversion price of $32.00. F2 · kind: Each share of Series B Preferred Stock was mandatorily converted on April 29, 2021 pursuant to the terms of the Series B Preferred Stock set forth in the Certificate of Designations of Series B Preferred Stock. F2 · derivative.expiration_date: Each share of Series B Preferred Stock was mandatorily converted on April 29, 2021 pursuant to the terms of the Series B Preferred Stock set forth in the Certificate of Designations of Series B Preferred Stock. Read SEC document |
| April 29, 2021 Filed Apr 29, 2021 20:06 UTC | TuHURA Biosciences, Inc./NV KTRA · Entity 6601 | ConversionCommon Stock | 750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000905718-21-000631 · kintara_fm4apr292021.xml · nonDerivative · entry 2 Brown Dennis M · CIK 0001569520 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,818 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Each share of Series B Preferred Stock was mandatorily converted on April 29, 2021 pursuant to the terms of the Series B Preferred Stock set forth in the Certificate of Designations of Series B Preferred Stock. F3 · price: Each share of Series B Preferred Stock was convertible into 0.25 shares of common stock equating to a conversion price of $32.00. Read SEC document |
| April 29, 2021 Filed Apr 29, 2021 20:06 UTC | TuHURA Biosciences, Inc./NV KTRA · Entity 6601 | OtherCommon Stock | 6 | $0.00 | $0.00 |
DisclosureSEC source: 0000905718-21-000631 · kintara_fm4apr292021.xml · nonDerivative · entry 1 Brown Dennis M · CIK 0001569520 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,068 F1 · kind: The shares were issued as dividends to April 29, 2021 on the reporting person's shares of Series B Preferred Stock. Read SEC document |
| March 31, 2021 Filed Mar 31, 2021 20:11 UTC | TuHURA Biosciences, Inc./NV KTRA · Entity 6601 | OtherCommon Stock | 17 | $0.00 | $0.00 |
DisclosureSEC source: 0000905718-21-000503 · kintara_fm4mar312021.xml · nonDerivative · entry 1 Brown Dennis M · CIK 0001569520 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,062 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. Read SEC document |
| December 31, 2020 Filed Jan 4, 2021 13:01 UTC | TuHURA Biosciences, Inc./NV KTRA · Entity 6601 | OtherCommon Stock | 17 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-000044 · doc4.xml · nonDerivative · entry 1 Brown Dennis M · CIK 0001569520 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,045 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. Read SEC document |
| December 29, 2020 Filed Jun 10, 2021 17:40 UTC | Cell Source, Inc. CLCS · Entity 9600 | OtherCommon Stock | 3,025 | $0.75 | $2,268.75 |
DisclosureSEC source: 0001493152-21-013985 · ownership.xml · nonDerivative · entry 3 Brown Dennis M · CIK 0001569520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,951 F1 · kind: Issued as payment-in-kind dividend on Series A Convertible Preferred Stock. Read SEC document |
| September 30, 2020 Filed Sep 30, 2020 20:05 UTC | TuHURA Biosciences, Inc./NV KTRA · Entity 6601 | OtherCommon Stock | 17 | $0.00 | $0.00 |
DisclosureSEC source: 0000905718-20-000997 · kintara_fm4sep302020.xml · nonDerivative · entry 1 Brown Dennis M · CIK 0001569520 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,028 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. Read SEC document |
| September 22, 2020 Filed Sep 24, 2020 23:31 UTC | TuHURA Biosciences, Inc./NV KTRA · Entity 6601 | GrantOptions (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $1.36 | $0.00 |
DisclosureSEC source: 0000905718-20-000984 · kintara_fm4sep222020.xml · derivative · entry 1 Brown Dennis M · CIK 0001569520 · Chief Scientifc Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2030-09-22 F1 · derivative.exercise_date: The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued employment, 1/6th of the options vest on March 22, 2021, with the remaining shares vesting in equal monthly installments over a period of 30 months commencing on April 22, 2021. Read SEC document |
| September 15, 2020 Filed Sep 18, 2020 01:08 UTC | TuHURA Biosciences, Inc./NV KTRA · Entity 6601 | GrantOptions (Right to Buy) · Derivative | 87,437 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0000905718-20-000971 · kintara_fm4sep152020.xml · derivative · entry 1 Brown Dennis M · CIK 0001569520 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,437 Underlying: Common Stock · 87,437 shares Expires 2030-09-15 F1 · derivative.exercise_date: The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued employment, 1/6th of the options vest on March 15, 2021, with the remaining shares vesting in equal monthly installments over a period of 30 months commencing on April 15, 2021. Read SEC document |
| August 19, 2020 Filed Jun 10, 2021 17:40 UTC | Cell Source, Inc. CLCS · Entity 9600 | GrantDirector Stock Option (Right to Buy) · Derivative | 450,000 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001493152-21-013985 · ownership.xml · derivative · entry 5 Brown Dennis M · CIK 0001569520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Stock · 450,000 shares Expires 2025-08-19 Read SEC document |
| June 30, 2020 Filed Jun 30, 2020 20:07 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | OtherCommon Stock | 17 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-20-016299 · ownership.xml · nonDerivative · entry 1 Brown Dennis M · CIK 0001569520 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,011 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. Read SEC document |
| June 30, 2020 Filed Jun 10, 2021 17:40 UTC | Cell Source, Inc. CLCS · Entity 9600 | OtherCommon Stock | 2,992 | $0.75 | $2,244.00 |
DisclosureSEC source: 0001493152-21-013985 · ownership.xml · nonDerivative · entry 2 Brown Dennis M · CIK 0001569520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,926 F1 · kind: Issued as payment-in-kind dividend on Series A Convertible Preferred Stock. Read SEC document |
| June 26, 2020 Filed Jun 30, 2020 20:07 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | GrantOptions (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $0.74 | $0.00 |
DisclosureSEC source: 0001213900-20-016299 · ownership.xml · derivative · entry 4 Brown Dennis M · CIK 0001569520 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2029-11-12 F5 · kind: On November 12, 2019, the reporting person received options to purchase 250,000 shares which were subject to stockholder approval of the increase in the number of shares authorized for issuance under the DelMar Pharmaceuticals, Inc. 2017 Omnibus Equity Incentive Plan, as amended, at the 2020 Annual Meeting of Stockholders. Stockholder approval of the increase was obtained on June 26, 2020. F6 · derivative.exercise_date: The options vested based on the achievement of certain clinical milestones. Read SEC document |
| June 26, 2020 Filed Jun 30, 2020 20:07 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | GrantOptions (Right to Buy) · Derivative | 52,756 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001213900-20-016299 · ownership.xml · derivative · entry 3 Brown Dennis M · CIK 0001569520 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 52,756 shares Expires 2029-09-05 F3 · kind: On September 5, 2019, the reporting person received options to purchase 52,756 shares which were subject to stockholder approval of the increase in the number of shares authorized for issuance under the DelMar Pharmaceuticals, Inc. 2017 Omnibus Equity Incentive Plan, as amended, at the 2020 Annual Meeting of Stockholders. Stockholder approval of the increase was obtained on June 26, 2020. F4 · derivative.exercise_date: 1/6th of the options vested on March 5, 2020 with the remaining shares vesting in equal monthly installments over a period of 30 months commencing on April 5, 2020. Read SEC document |
| March 31, 2020 Filed Mar 31, 2020 20:15 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | OtherCommon Stock | 17 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-20-008213 · ownership.xml · nonDerivative · entry 1 Brown Dennis M · CIK 0001569520 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,994 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. Read SEC document |
| December 31, 2019 Filed Jan 2, 2020 21:20 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | OtherCommon Stock | 17 | $0.00 | $0.00 |
DisclosureSEC source: 0000905718-20-000020 · delmarph_fm4dec312019.xml · nonDerivative · entry 2 Brown Dennis M · CIK 0001569520 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,977 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. Read SEC document |
| December 31, 2019 Filed Jun 10, 2021 17:40 UTC | Cell Source, Inc. CLCS · Entity 9600 | OtherCommon Stock | 5,934 | $0.75 | $4,450.50 |
DisclosureSEC source: 0001493152-21-013985 · ownership.xml · nonDerivative · entry 1 Brown Dennis M · CIK 0001569520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,934 F1 · kind: Issued as payment-in-kind dividend on Series A Convertible Preferred Stock. Read SEC document |
| December 27, 2019 Filed Jan 2, 2020 21:20 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | GiftCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000905718-20-000020 · delmarph_fm4dec312019.xml · nonDerivative · entry 1 Brown Dennis M · CIK 0001569520 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,960 Read SEC document |
| November 12, 2019 Filed Nov 14, 2019 21:18 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | GrantOptions (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $0.74 | $0.00 |
DisclosureSEC source: 0000905718-19-000941 · delmarph_fm4nov122019.xml · derivative · entry 1 Brown Dennis M · CIK 0001569520 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2029-11-12 F1 · derivative.exercise_date: Subject to stockholder approval of the increase in the number of shares authorized for issuance under the DelMar Pharmaceuticals, Inc. 2017 Omnibus Equity Incentive Plan, as amended, at the next annual meeting, the options vest upon the achievement of certain clinical development milestones. Read SEC document |
| November 12, 2019 Filed Sep 24, 2020 23:28 UTC Amendment | TuHURA Biosciences, Inc./NV KTRA · Entity 6601 | GrantOptions (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $0.74 | $0.00 |
DisclosureSEC source: 0000905718-20-000982 · kintara_fm4anov142019.xml · derivative · entry 1 Brown Dennis M · CIK 0001569520 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2029-11-12 F1 · derivative.exercise_date: This amendment is being filed to update the vesting schedule of the option award made to the reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued employment, 1/6th of the options vested on March 22, 2021, with the remaining shares vesting in equal monthly installments over a period of 30 months commencing on April 22, 2021. Read SEC document |
| September 30, 2019 Filed Oct 1, 2019 20:09 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | OtherCommon Stock | 17 | $0.00 | $0.00 |
DisclosureSEC source: 0000905718-19-000809 · delmarph_fm4sept302019.xml · nonDerivative · entry 1 Brown Dennis M · CIK 0001569520 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,460 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. Read SEC document |
| September 05, 2019 Filed Sep 9, 2019 20:42 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | GrantOptions (Right to Buy) · Derivative | 47,244 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0000905718-19-000765 · delmarph_fm4sept52019.xml · derivative · entry 2 Brown Dennis M · CIK 0001569520 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,244 Underlying: Common Stock · 47,244 shares Expires 2029-09-05 F2 · derivative.exercise_date: 1/6th of the options vest on March 5, 2020 with the remaining shares vesting in equal monthly installments over a period of 30 months commencing on April 5, 2020. Read SEC document |
| September 05, 2019 Filed Sep 9, 2019 20:42 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | GrantOptions (Right to Buy) · Derivative | 52,756 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0000905718-19-000765 · delmarph_fm4sept52019.xml · derivative · entry 1 Brown Dennis M · CIK 0001569520 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,756 Underlying: Common Stock · 52,756 shares Expires 2029-09-05 F1 · derivative.exercise_date: Subject to stockholder approval of the increase in the number of shares authorized for issuance under the DelMar Pharmaceuticals, Inc. 2017 Omnibus Equity Incentive Plan, as amended, at the next annual meeting, 1/6th of the options vest on March 5, 2020 with the remaining shares vesting in equal monthly installments over a period of 30 months commencing on April 5, 2020. Read SEC document |
| June 28, 2019 Filed Jul 1, 2019 20:18 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | OtherCommon Stock | 17 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-19-011878 · ownership.xml · nonDerivative · entry 1 Brown Dennis M · CIK 0001569520 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,443 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. F2 · balance_after: On May 8, 2019, the issuer effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| March 29, 2019 Filed Apr 1, 2019 20:34 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | OtherCommon Stock | 169 | $0.49 | $82.81 |
DisclosureSEC source: 0001213900-19-005499 · ownership.xml · nonDerivative · entry 1 Brown Dennis M · CIK 0001569520 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,260 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. Read SEC document |
| February 13, 2019 Filed Jun 10, 2021 17:40 UTC | Cell Source, Inc. CLCS · Entity 9600 | GrantSeries A Convertible Preferred Stock · Derivative | 6,667 | $7.50 Strike: $0.75 | $50,002.50 |
DisclosureSEC source: 0001493152-21-013985 · ownership.xml · derivative · entry 4 Brown Dennis M · CIK 0001569520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,667 Underlying: Common Stock · 66,670 shares Expires not disclosed F2 · derivative.expiration_date: The Series A Convertible Preferred Stock has no expiration date. Read SEC document |
| December 31, 2018 Filed Jan 2, 2019 23:16 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | OtherCommon Stock | 169 | $0.34 | $57.78 |
DisclosureSEC source: 0001213900-19-000049 · ownership.xml · nonDerivative · entry 2 Brown Dennis M · CIK 0001569520 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,091 F2 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. Read SEC document |
| December 21, 2018 Filed Jan 2, 2019 23:16 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | GiftCommon Stock | 85,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-19-000049 · ownership.xml · nonDerivative · entry 1 Brown Dennis M · CIK 0001569520 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,922 F1 · kind: This transaction represents a gift of securities made by the Reporting Person. Read SEC document |
| September 28, 2018 Filed Oct 1, 2018 20:07 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | OtherCommon Stock | 169 | $3.20 | $540.80 |
DisclosureSEC source: 0001213900-18-013295 · ownership.xml · nonDerivative · entry 1 Brown Dennis M · CIK 0001569520 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,922 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. Read SEC document |
| June 29, 2018 Filed Jul 3, 2018 20:38 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | OtherCommon Stock | 169 | $3.20 | $540.80 |
DisclosureSEC source: 0001213900-18-008710 · ownership.xml · nonDerivative · entry 1 Brown Dennis M · CIK 0001569520 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,753 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. Read SEC document |
| March 30, 2018 Filed Apr 3, 2018 20:04 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | OtherCommon Stock | 169 | $3.20 | $540.80 |
DisclosureSEC source: 0001213900-18-003982 · f4033018brown_delmar.xml · nonDerivative · entry 1 Brown Dennis M · CIK 0001569520 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,584 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. Read SEC document |
| December 31, 2017 Filed Jan 3, 2018 22:00 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | OtherCommon Stock | 169 | $3.20 | $540.80 |
DisclosureSEC source: 0000905718-18-000016 · brown_form4dec132017.xml · nonDerivative · entry 2 Brown Dennis M · CIK 0001569520 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,415 F2 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. F2 · price: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. Read SEC document |
| December 13, 2017 Filed Jan 3, 2018 22:00 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | GiftCommon Stock | 129,600 | $0.00 | $0.00 |
DisclosureSEC source: 0000905718-18-000016 · brown_form4dec132017.xml · nonDerivative · entry 1 Brown Dennis M · CIK 0001569520 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,246 F1 · kind: This transaction involved a gift of securities by the Reporting Person to his adult children, and an adult custodian of family members. This disposition was made for estate planning purposes. F1 · price: This transaction involved a gift of securities by the Reporting Person to his adult children, and an adult custodian of family members. This disposition was made for estate planning purposes. Read SEC document |
| September 29, 2017 Filed Oct 2, 2017 23:54 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | OtherCommon Stock | 169 | $3.20 | $540.80 |
DisclosureSEC source: 0001213900-17-010212 · f4092917brown_delmarpharm.xml · nonDerivative · entry 1 Brown Dennis M · CIK 0001569520 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Note Disclosed balance after: 885,346 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. F1 · price: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. F2 · ownership.nature: Includes 347,846 shares of the Issuer's common stock owned directly by reporting person and 537,500 shares of the Issuer's common stock held by Valent Technologies LLC, of which Reporting Person is the sole member and owner and holds sole voting and dispositive power over its shares. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 18:25 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | OtherCommon Stock | 169 | $3.20 | $540.80 |
DisclosureSEC source: 0001213900-17-007143 · f4063017brown_delmarpharma.xml · nonDerivative · entry 1 Brown Dennis M · CIK 0001569520 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Note Disclosed balance after: 885,177 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. F1 · price: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. F2 · ownership.nature: Includes 347,677 shares of the Issuer's common stock owned directly by reporting person and 537,500 shares of the Issuer's common stock held by Valent Technologies LLC, of which Reporting Person is the sole member and owner and holds sole voting and dispositive power over its shares. Read SEC document |
| March 31, 2017 Filed Apr 3, 2017 22:13 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | OtherCommon Stock | 169 | $3.20 | $540.80 |
DisclosureSEC source: 0001213900-17-003266 · f4033117brown_delmar.xml · nonDerivative · entry 1 Brown Dennis M · CIK 0001569520 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Note Disclosed balance after: 885,008 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. F1 · price: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. F2 · ownership.nature: Includes 347,508 shares of the Issuer's common stock owned directly by reporting person and 537,500 shares of the Issuer's common stock held by Valent Technologies LLC, of which Reporting Person is the sole member and owner and holds sole voting and dispositive power over its shares. Read SEC document |
| February 17, 2017 Filed Feb 22, 2017 21:23 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | GrantOptions (Right to Buy) · Derivative | 93,600 | $0.00 Strike: $4.95 | $0.00 |
DisclosureSEC source: 0001213900-17-001708 · f4021717brown_delmarpharma.xml · derivative · entry 1 Brown Dennis M · CIK 0001569520 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,600 Underlying: Common Stock · 93,600 shares Expires 2027-02-17 F1 · derivative.exercise_date: The options vest in equal monthly installments over three years. Read SEC document |
| January 31, 2017 Filed Feb 2, 2017 21:31 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | ConversionWarrants (Right to buy) · Derivative | 125,000 | $0.00 Strike: $1.54 | $0.00 |
DisclosureSEC source: 0001213900-17-000886 · f4013117brown_delmarpharm.xml · derivative · entry 2 Brown Dennis M · CIK 0001569520 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 125,000 shares Expires 2017-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The exercise price of the warrants was CDN $2.00. $1.5366 represents the exercise price in USD based on the exchange rate as of the exercise date. F2 · ownership.nature: Warrants were held by Valent Technologies LLC. Read SEC document |
| January 31, 2017 Filed Feb 2, 2017 21:31 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | ConversionCommon Stock | 125,000 | $1.54 | $192,075.00 |
DisclosureSEC source: 0001213900-17-000886 · f4013117brown_delmarpharm.xml · nonDerivative · entry 1 Brown Dennis M · CIK 0001569520 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Note Disclosed balance after: 884,839 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: The exercise price of the warrants was CDN $2.00. $1.5366 represents the exercise price in USD based on the exchange rate as of the exercise date. F1 · ownership.nature: Includes 347,339 shares of the Issuer's common stock owned directly by reporting person and 537,500 shares of the Issuer's common stock held by Valent Technologies LLC, of which Reporting Person is the sole member and owner and holds. Read SEC document |
| December 31, 2016 Filed Jan 3, 2017 18:55 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | OtherCommon Stock | 169 | $3.20 | $540.80 |
DisclosureSEC source: 0001213900-17-000023 · f4123116brown_delmar.xml · nonDerivative · entry 1 Brown Dennis M · CIK 0001569520 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Note Disclosed balance after: 759,839 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. F1 · price: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. F2 · ownership.nature: Includes 347,339 shares of the Issuer's common stock owned directly by reporting person and 412,500 shares of the Issuer's common stock held by Valent Technologies LLC, of which Reporting Person is the sole member and owner and holds sole voting and dispositive power over its shares. Read SEC document |
| October 03, 2016 Filed Oct 5, 2016 16:32 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | OtherCommon Stock | 169 | $3.20 | $540.80 |
DisclosureSEC source: 0001213900-16-017298 · f4100316brown_delmarpharm.xml · nonDerivative · entry 1 Brown Dennis M · CIK 0001569520 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Note Disclosed balance after: 759,670 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. F1 · price: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. F2 · ownership.nature: Includes 347,170 shares of the Issuer's common stock owned directly by reporting person and 412,500 shares of the Issuer's common stock held by Valent Technologies LLC, of which Reporting Person is the sole member and owner and holds sole voting and dispositive power over its shares. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.